Bad Seed: the ADVANTAGE Trial of Vioxx

Courtesy Health Care Renewal  Tue, 08/19/2008 - 14:12

An article in the Annals of Internal Medicine by Hill et al(1), and the accompanying editorial by Sox and Rennie(2) have created quite a stir in the media and blogsphere.

Even so, it seems worth reviewing the main points, and adding some comments.

Hill et al address the ADVANTAGE trial, published in the Annals in 2003.(3) This was a randomized controlled trial that compared rofecoxib (Vioxx, by Merck) to naproxen for patients with osteoarthritis. 600 investigators each enrolled a...

Tags:

 

More related items

ADVANTAGE: Who was actually in charge of R&D? And other...
Roy Poses addresses many of the controversial issues raised by the Annals of Internal Medicine article "The ADVANTAGE seeding trial: a review of...

Key Opinion Leaders, Drugs for Smoking Cessation, and...
A perspectives article from the April 1 issue of the Annals of Internal Medicine has provoked a slowly growing controversy. (1) Let me summarize the...

Americans must consider cost and effectiveness when comparing...
(American College of Physicians) The American College of Physicians proposed today a means to improve physician and patient access to and use of...

BLOGSCAN - Disease Mongering and Indefinite Use of Smoking...
On the Bioethics Forum, Dr Adriane Fugh-Berman and Dr Douglas Melnick discuss what appears to be the latest example of disease-mongering. An article...

A Healthy Horse the Natural Way: A Horse Owner's Guide to Using...

What Your Doctor May Not Tell You About Fibromyalgia: The...
In this book Dr. R. Paul St. Amand offers the first effective protocol to help reverse the autoimmune disorder, Fibromyalgia, in children. The...

Good Calories, Bad Calories
In this groundbreaking book, the result of seven years of research in every science connected with the impact of nutrition on health, award-winning...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com